The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 26, 2021
Filed:
Nov. 08, 2017
Applicants:
Osaka University, Suita, JP;
Knc Laboratories Co., Ltd., Kobe, JP;
Inventors:
Haruo Sugiyama, Suita, JP;
Fumihiro Fujiki, Suita, JP;
Masahiro Neya, Kobe, JP;
Shinya Kohno, Kobe, JP;
Assignees:
OSAKA UNIVERSITY, Suita, JP;
KNC LABORATORIES CO., LTD., Kobe, JP;
Primary Examiner:
Int. Cl.
CPC ...
C07J 63/00 (2006.01); A61P 35/00 (2006.01); A61K 31/16 (2006.01); A61K 31/166 (2006.01); A61K 31/196 (2006.01); A61K 31/215 (2006.01); A61K 31/216 (2006.01); A61K 31/265 (2006.01); A61K 31/27 (2006.01); A61K 31/40 (2006.01); A61K 31/445 (2006.01); A61K 31/5375 (2006.01); C12N 5/0783 (2010.01); A61K 31/19 (2006.01); A61P 37/04 (2006.01); A61P 31/00 (2006.01); A61K 31/44 (2006.01);
U.S. Cl.
CPC ...
C07J 63/008 (2013.01); A61K 31/16 (2013.01); A61K 31/166 (2013.01); A61K 31/19 (2013.01); A61K 31/196 (2013.01); A61K 31/215 (2013.01); A61K 31/216 (2013.01); A61K 31/265 (2013.01); A61K 31/27 (2013.01); A61K 31/40 (2013.01); A61K 31/44 (2013.01); A61K 31/445 (2013.01); A61K 31/5375 (2013.01); A61P 31/00 (2018.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07J 63/00 (2013.01); C12N 5/0636 (2013.01); C12N 2501/39 (2013.01);
Abstract
Provided are: a compound represented by formula (I); a retinoid metabolic pathway inhibitor comprising the same; an agent for increasing the ratio of memory T cells; a prophylactic and/or therapeutic agent for cancer or an infectious disease; a cancer immunotherapeutic adjuvant; an immunopotentiator; and a method for preparing a T cell population wherein the ratio of memory T cells is increased, said method comprising using the compound of formula (I).